Jove
Visualize
Contáctanos

Videos de Conceptos Relacionados

Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Handwriting patterns in isolated rapid eye movement sleep behaviour disorder.

Journal of Parkinson's disease·2026
Same author

Beyond Pathology: α-Synuclein Homeostasis and Three Principles to Guide Research.

Movement disorders clinical practice·2025
Same author

'Pathology is disease' Parkinson's mythology: The 'brain-first-body-first' case study.

Journal of Parkinson's disease·2025
Same author

Licensed Subcutaneous Infusion Therapies in Advanced Parkinson's Disease: An Indirect Treatment Comparison and Cost-Minimisation Analysis.

Neurology and therapy·2025
Same author

Refutation of the αSyn-SAA-Based Staging for Parkinson's Progression (Neuronal α-Synuclein Disease-Integrated Staging System [NSD-ISS]).

Movement disorders : official journal of the Movement Disorder Society·2025
Same author

The resurrection of apomorphine: A dopamine analogue comparable in potency to L-DOPA.

Parkinsonism & related disorders·2025
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Ver todos los artículos relacionados
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Video Experimental Relacionado

Updated: Jun 22, 2026

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

Enfermedad de Parkinson enfermedad de Parkinson.

Andrew J Lees1, John Hardy, Tamas Revesz

  • 1Department of Molecular Neuroscience and Reta Lila Weston Institute of Neurological Studies, Institute of Neurology, University College London and the National Hospital for Neurology and Neurosurgery, London, UK. alees@ion.ucl.ac.uk

Lancet (London, England)
|June 16, 2009
PubMed
Resumen
Este resumen es generado por máquina.

La enfermedad de Parkinson, un trastorno neurodegenerativo común, implica la pérdida de células cerebrales y la acumulación de alfa-sinucleína. Los tratamientos manejan los síntomas motores y mejoran la calidad de vida, con células madre y terapia génica que muestran una promesa futura.

Más Videos Relacionados

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Videos de Experimentos Relacionados

Last Updated: Jun 22, 2026

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Área de la Ciencia:

  • Neurología Neurología.
  • La neurociencia es la neurociencia.
  • Genética La genética.

Sus antecedentes:

  • La enfermedad de Parkinson es un trastorno bradikinético progresivo.
  • Las principales características patológicas incluyen la pérdida de células negras y la agregación de alfa-sinucleína.
  • La edad es el principal factor de riesgo, y la predisposición genética también juega un papel importante.

Objetivo del estudio:

  • Para resumir las características clave, los factores de riesgo y los enfoques terapéuticos para la enfermedad de Parkinson.
  • Para resaltar la precisión del diagnóstico y la base patológica del trastorno.
  • Para discutir las estrategias de tratamiento actuales y emergentes.

Principales métodos:

  • Revisión de la literatura existente sobre la patología de la enfermedad de Parkinson y la presentación clínica.
  • Análisis de los factores genéticos que contribuyen a la susceptibilidad a las enfermedades.
  • Evaluación de las actuales intervenciones terapéuticas y las futuras direcciones de investigación.

Principales resultados:

  • La enfermedad de Parkinson se caracteriza por cambios neuropatológicos específicos.
  • La edad y los factores genéticos (por ejemplo, LRRK-2, GBA) son cruciales en el desarrollo de la enfermedad.
  • La terapia de reemplazo de dopamina y el manejo de los síntomas no motores mejoran los resultados de los pacientes.

Conclusiones:

  • Es posible lograr un diagnóstico preciso de la enfermedad de Parkinson.
  • Comprender la susceptibilidad genética es vital para la investigación de la enfermedad de Parkinson.
  • Las terapias emergentes como las células madre y la terapia génica ofrecen potencial para futuros tratamientos.